Regulatory and safety status: AOD 9604 is currently awaiting FDA review
The post hoc analysis of pooled data from the Semaglutide Treatment Effect in People with Obesity (STEP) 1, 2, 3, and 5 trials indicated that semaglutide treatment at 2.4 mg did not increase the risk of depressive symptoms or suicidal ideation compared to placebo, while demonstrating a statistically significant yet clinically negligible decrease in depressive symptoms [75]
Let me tell y'all that this here is the real deal and really works
Gastroenterology & Hepatology 15(1): 11 [PubMed] Younossi ZM, Wong VW, Anstee QM, Romero-Gomez M, Trauner MH, Harrison SA, Lawitz EJ, Okanoue T, Camargo M, Kersey K, Myers RP, Goodman Z, Stepanova M (2020) Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: The impact on patient-reported outcomes
Prescribing decisions are made solely by evaluating clinicians, and prescriptions are not guaranteed